Rare pancreatic cancer patients may live longer when treated with radiation therapyNovember 23, 2009Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO). PNT is a very rare form of pancreatic cancer that can stay confined to the liver and often cause death from liver damage. Since it is usually unable to be removed by surgery, external beam radiation therapy (EBRT) is an attractive option for managing the disease, but the role of EBRT is largely unknown because of the low incidence of this tumor type and, as a result, very few related studies. Researchers at the departments of radiation oncology and internal medicine, division of hematology/oncology and comprehensive cancer center biostatistics unit at the University of Michigan in Ann Arbor, Mich., sought to determine if PNTs are not as resistant to radiation therapy as was previously thought. Records from 36 patients with PNTs who were treated between 1986 and 2006 with radiation therapy to 49 sites were reviewed and it was found that in 39 percent of patients the tumor shrunk to less than half its pretreatment size after being treated with EBRT. Also, radiation therapy treatments achieved high rates of local control and 90 percent of patients experienced palliation of symptoms such as pain, nausea, vomiting or obstructive jaundice. Theodore S. Lawrence, M.D., Ph.D., FASTRO, an author on the study and chair of the University of Michigan Department of Radiation Oncology, said, "While this particular type of cancer can have potentially devastating effects on a patient, this study proves that using external beam radiation therapy may permit these patients to live longer, which is a very positive breakthrough for a disease that can have very negative outcomes." American Society for Radiation Oncology |
|||||||||||||||||||||
| Related Radiation Therapy Current Events and Radiation Therapy News Articles Lower detection of prostate cancer with PSA screening in US than in a European randomized trial Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute. Curing More Cervical Cancer Cases May be in the Math Cervical cancer is highly curable when caught early. But in a third of cases, the tumor responds poorly to therapy or recurs later, when cure is much less likely. AAPM statement on quality radiation therapy The American Association of Physicists in Medicine (AAPM) has issued a statement today in the wake of several recent articles in the New York Times yesterday and earlier in the week that discuss a number of rare but tragic events in the last decade involving people undergoing radiation therapy. Sexual function does not continuously decline after radiation therapy treatments for prostate cancer Sexual function in prostate cancer patients receiving external beam radiation therapy (EBRT) decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought. Report suggests similar effectiveness among options for managing low-risk prostate cancer A comprehensive appraisal of the management and treatment options for low-risk prostate cancer found that the rates of survival and tumor recurrence are similar among the most common treatment approaches, although costs can vary considerably. Radiofrequency ablation safe and effective for reducing pain from bone metastases Image-guided radiofrequency ablation (RFA), a minimally invasive cancer treatment which can be performed in the outpatient setting, significantly reduced the level of pain experienced by cancer patients with bone (osseous) metastases, limiting the need for strong narcotic pain management, and supporting improved patient frame of mind. Experimental drug shows promise against brain, prostate cancers An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies. UGA Study finds significantly worse outcomes in cancer patients with cognitive impairment A new study published by researchers from the University of Georgia and the Moffitt Cancer Center in Tampa, Fla., has found that cancer patients with dementia have a dramatically lower survival rate than patients with cancer alone, even after controlling for factors such as age, tumor type and tumor stage. Study finds racial disparities exist in radiation therapy rates for early stage breast cancer Black women are less likely than white women to receive radiation therapy after a lumpectomy, the standard of care for early stage breast cancer, according to a new study by researchers at The University of Texas M. D. Anderson Cancer Center. Jefferson neurosurgeon helps draft new treatment guidelines for brain metastases New treatment guidelines for patients with brain metastases are now available from the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS). David Andrews, M.D., F.A.C.S., professor and vice-chair of Clinical Services in the Department of Neurological Surgery at Jefferson Hospital for Neuroscience, served as a member of the task force chosen to draft this new, significant tool to improve the quality of care for patients who suffer from brain tumors. More Radiation Therapy Current Events and Radiation Therapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||